- Anticipated market launch by end of April 2013
- Patent allowance extends coverage to 2032
Under proposed transaction's terms, Horizon Pharma would acquire all outstanding shares of Depomed for $29.25 each in an all-stock transaction, a 42% premium to its closing price on Monday.
Large pharmas continued the shopping spree, paying no attention to whispers of a biotech bubble.
Stocks recapture positive territory for the year.